Medicare Part D GLP-1 coverage policy and the 2026 Bridge

Medicare Part D spending on GLP-1 receptor agonists rose from $57 million in 2018 to $5.7 billion in 2022, making incretin therapies one of the fastest-growing cost drivers in the Part D benefit. Yet a statutory exclusion bars Medicare from covering drugs used for weight loss, even when the FDA has approved them for obesity treatment. The result is a bifurcated coverage system: Ozempic and Mounjaro are covered for type 2 diabetes, Wegovy is covered for cardiovascular risk reduction and MASH but not for weight loss, and Zepbound is excluded entirely — unless the patient qualifies for the new CMS GLP-1 Bridge demonstration starting July 1, 2026.

This policy guide is for market access teams, payer strategists, benefit verification specialists, and prescribers who need to understand how Medicare Part D covers GLP-1 drugs in 2026, what the GLP-1 Bridge changes, and what to monitor as CMS and Congress weigh permanent coverage expansion. It is not medical advice or reimbursement guidance for a specific patient or plan.

Quick answer

Who this is for

• Market access and government affairs teams at GLP-1 manufacturers

• Medicare Advantage plan formulary committees and pharmacy directors

• Benefit verification specialists handling Part D GLP-1 PA submissions

• Prescribers (endocrinologists, cardiologists, primary care) treating Medicare beneficiaries

• Policy analysts tracking CMS demonstration programs

Source standard

Every fact in this guide is sourced from CMS policy documents, the Federal Register, Congressional Research Service reports, peer-reviewed research, and payer policy documents dated 2025–2026. Coverage rules change frequently. Always verify current formulary and PA criteria on the specific Part D plan's portal.

The statutory weight-loss exclusion

The Medicare Modernization Act of 2003 (MMA) excluded drugs used for "anorexia, weight loss, or weight gain" from Part D coverage. This statutory bar has prevented Medicare from covering FDA-approved anti-obesity medications, even as the GLP-1 class gained obesity indications:

• 2014: Saxenda (liraglutide) approved for chronic weight management — excluded from Part D

• 2021: Wegovy (semaglutide 2.4 mg) approved for chronic weight management — excluded from Part D

• 2023: Zepbound (tirzepatide) approved for chronic weight management — excluded from Part D

The exclusion applies to the indication, not the molecule. The same drug can be covered for one indication and excluded for another. Wegovy is a single molecule (semaglutide) that is covered for cardiovascular risk reduction and MASH but excluded for weight management.

The Biden Administration proposed lifting the weight-loss exclusion as part of the 2026 Medicare Part D proposed rule, but the Trump Administration declined to finalize that proposal, stating it "is not appropriate at this time." As a result, the statutory weight-loss exclusion remains in effect for standard Part D coverage.

Part D coverage for approved indications

Type 2 diabetes

Part D plans are required to cover at least two drugs in each therapeutic category used for T2D, but they are not required to include any specific GLP-1 drug. Coverage depends on whether the drug is listed on the plan's formulary:

• Ozempic: Listed on most Part D formularies for T2D. Prior authorization is common

• Mounjaro: Listed on an increasing number of Part D formularies for T2D. PA required

• Rybelsus: Oral semaglutide is covered on most plans for T2D

• Trulicity: Widely covered for T2D

• Foundayo (orforglipron): New-to-market oral GLP-1 approved for chronic weight management; T2D submission pending. Covered under the GLP-1 Bridge for obesity; T2D formulary coverage expanding through 2026

Cardiovascular risk reduction

Wegovy is the only GLP-1 drug with an FDA-approved indication specifically for reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease who are overweight or obese. This indication is a covered Part D benefit:

• Part D plans that carry Wegovy on formulary must cover it for the CV indication

• PA criteria typically require documentation of established CVD and overweight/obesity

• The CV indication creates a coverage pathway for Wegovy that does not depend on weight-loss language

MASH (metabolic dysfunction-associated steatohepatitis)

Wegovy received FDA approval for treatment of noncirrhotic MASH, creating another covered indication under Part D:

• Coverage requires a MASH diagnosis (documented by liver biopsy or non-invasive assessment)

• This indication is separate from the weight-loss and CV indications

• Access teams should verify whether the specific Part D plan has updated its PA criteria to include the MASH indication

Prior authorization trends

A cross-sectional study published in JAMA examined PA trends for GLP-1 therapies under Medicare Part D. Key findings:

• PA requirements for injectable semaglutide (Ozempic) under Medicare Part D have been increasing year over year

• PA rates vary significantly across Part D plans, creating access disparities for beneficiaries in different plans

• Pennsylvania eliminated Medicaid GLP-1 coverage for weight loss starting January 2026; similar state-level restrictions may follow

Common Part D PA criteria for GLP-1 drugs

The Medicare GLP-1 Bridge demonstration

Overview

CMS announced the Medicare GLP-1 Bridge as part of the broader BALANCE model in December 2025, and formally launched enrollment on May 6, 2026. The Bridge is a time-limited demonstration program that will provide eligible Part D beneficiaries access to certain GLP-1 drugs for weight management. Key parameters:

• Program dates: July 1, 2026 through December 31, 2027

• Copay: $50 per monthly supply for eligible beneficiaries

• Manufacturer net price: $245 per monthly supply (paid by participating manufacturers)

• Eligible drugs: The Bridge covers GLP-1 drugs FDA-approved for weight loss. Participating medications include all formulations of Wegovy (pill and injectable), the KwikPen formulation of Zepbound, and all formulations of Foundayo. Note: Ozempic and Mounjaro are excluded from the Bridge because they carry diabetes-branded indications, not FDA-approved obesity indications. Rybelsus is also excluded

• Operation: The Bridge operates outside the standard Part D benefit's coverage and payment flow. Part D sponsors do not carry risk for Bridge drugs and do not have to opt in for eligible beneficiaries to access them

• Central processor: CMS will use a single central processor to manage PA, claims adjudication, and pharmacy payment for Bridge drugs

Eligibility criteria

CMS has established the following eligibility requirements for the GLP-1 Bridge:

• Enrolled in a Medicare Part D prescription drug plan

• Meets clinical criteria for GLP-1 therapy as determined by the prescribing provider

• Prior authorization required (processed through the Bridge's central processor, not the Part D plan)

• Drug must be on the Bridge's list of eligible GLP-1 products

What the Bridge does not change

• The statutory weight-loss exclusion remains in effect for standard Part D coverage

• The Bridge is a demonstration program, not a permanent policy change

• Part D plans are not required to add weight-loss GLP-1s to their formularies

• The Bridge does not cover GLP-1 drugs for T2D (those remain under standard Part D coverage)

• Coverage under the Bridge ends when the demonstration ends (December 31, 2027), unless extended

Access implications

For market access teams, the GLP-1 Bridge creates several operational considerations:

• PA pathway: The Bridge uses a separate PA process from standard Part D. Prescribers will need to submit PA through the Bridge's central processor, not the Part D plan's standard PA channel

• Pharmacy network: CMS has not yet specified which pharmacies will dispense Bridge drugs. Specialty pharmacy requirements may apply

• Formulary positioning: Manufacturers should consider how Bridge participation affects their commercial formulary positioning and contracting strategy

• Data collection: CMS will collect utilization and outcomes data during the demonstration, which may inform future permanent coverage decisions

Part D plan formulary dynamics

Formulary tier placement

GLP-1 drugs are typically placed on specialty tiers in Part D plans:

• Tier 3 (Preferred Brand): Some plans place preferred GLP-1s (often Ozempic) at preferred brand tier to manage costs

• Tier 4 (Non-Preferred Brand): Non-preferred GLP-1s may be placed at non-preferred tier with higher cost sharing

• Tier 5 (Specialty): Many plans use a dedicated specialty tier for GLP-1 drugs, with coinsurance rather than copay

Under the 2026 Part D redesign, the annual out-of-pocket cap is $2,100. Beneficiaries on specialty-tier GLP-1s may face significant coinsurance before reaching the cap, although manufacturer copay assistance programs can offset costs for some patients.

Plan-level coverage variation

Not all Part D plans include every GLP-1 drug on formulary. The Congressional Research Service found that while Part D plans generally cover GLP-1s for T2D and CV indications, formulary inclusion varies:

• Some plans cover Ozempic but not Mounjaro

• Some plans cover Wegovy only for the CV indication, not for MASH

• Plan formularies can change at annual renewal (January 1) or mid-year with CMS notification

• Beneficiaries should verify formulary status during annual enrollment

Medicaid comparison

Medicaid GLP-1 coverage is state-specific and in active transition:

• T2D indication: Generally covered with PA across states

• Weight-loss indication: Multiple states have restricted or eliminated GLP-1 coverage for weight loss starting in 2026

• Notable changes: Medi-Cal excluded GLP-1s for weight loss effective January 1, 2026; Pennsylvania restricted Medicaid GLP-1 coverage for weight loss starting January 2026

• Wegovy for MASH and CV: Some states retain Wegovy coverage for MASH and CV indications even when excluding weight-loss coverage

The state-level Medicaid restrictions parallel the federal Part D weight-loss exclusion but are implemented independently by each state.

What changed recently

• CMS GLP-1 Bridge enrollment launch (May 2026): CMS formally launched enrollment for the Medicare GLP-1 Bridge on May 6, 2026, providing $50/month access to eligible GLP-1 drugs for Medicare Part D beneficiaries starting July 1, 2026. The broader BALANCE model was initially announced in December 2025

• MASH indication for Wegovy: FDA approval for noncirrhotic MASH creates a new covered indication under Part D that does not depend on the weight-loss pathway

• Foundayo (orforglipron) launch: The first oral non-peptide GLP-1 receptor agonist received FDA approval for chronic weight management (obesity), expanding the GLP-1 class and potentially shifting Part D formulary dynamics. A T2D indication is under regulatory review

• Weight-loss exclusion not lifted: The Trump Administration declined to finalize the proposed removal of the Part D weight-loss exclusion, maintaining the status quo

• Part D PA stringency increasing: Research from the Leonard Davis Institute at the University of Pennsylvania shows that Part D plans are increasing PA requirements for GLP-1 drugs, potentially in response to rising utilization and spending

What to monitor next

• GLP-1 Bridge implementation details: CMS has not yet published the full eligible drug list, PA criteria, pharmacy network, or operational guidance for the Bridge. Monitor CMS.gov for updates before the July 1, 2026 launch

• Congressional action on weight-loss exclusion: Multiple bills have been introduced to lift the Part D weight-loss exclusion permanently. Monitor Congressional activity for legislative movement

• Part D formulary changes for 2027: Plans may adjust GLP-1 formulary positioning for the 2027 plan year in response to the Bridge demonstration and new indications

• IRA negotiation implications: CMS selected Ozempic, Rybelsus, and Wegovy for the second round of IRA Medicare drug price negotiations. The negotiated prices effective January 1, 2027 will be $274 for a 30-day supply, according to AARP reporting. This could significantly affect formulary positioning, PA stringency, and beneficiary cost sharing across Part D plans

• State Medicaid GLP-1 policy: Monitor state Medicaid agency websites for coverage changes that may parallel or diverge from federal Part D policy

• New GLP-1 indications: Ozempic's peripheral artery disease indication (still pending) and CagriSema's potential approval could expand the scope of covered Part D GLP-1 indications

Sources

• CMS. Medicare GLP-1 Bridge. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

• CMS Newsroom. Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries

• Congressional Research Service. Medicare Coverage of GLP-1 Drugs. IF12758. September 2024. https://www.congress.gov/crs-product/IF12758

• PMC / JAMA. Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888

• Leonard Davis Institute, University of Pennsylvania. Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic

• American College of Gastroenterology. Anti-Obesity Drugs Will Not be Covered by Medicare and Medicaid in 2026. https://gi.org/2025/04/17/anti-obesity-drugs-will-not-be-covered-by-medicare-and-medicaid-in-2026

• KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid

• NPR. Medicare to Launch Weight Loss Drug Option in July with $50 Copay. May 2026. https://www.npr.org/2026/05/06/nx-s1-5812662/medicare-bridge-glp1-drugs-copay

• AARP. Does Medicare Cover Ozempic, Other Weight Loss Drugs? https://www.aarp.org/medicare/does-medicare-cover-ozempic-weight-loss-drugs

• Wellcare. Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026. https://www.wellcare.com/en/resources/does-medicare-cover-weight-loss-drugs

• Congress.gov. Medicare Coverage of GLP-1 Drugs — In Focus. https://www.congress.gov/crs-product/IF12758

• Absolute Best Insurance. Medicare News Alert: GLP-1 Weight Loss Drug Coverage Is Coming. May 2026. https://absolutebestins.com/medicare-weight-loss-drug-coverage

• Universal Drugstore. Can Someone on Medicare Get Weight Loss Medication? https://www.universaldrugstore.com/blog/can-someone-on-medicare-age-64-get-weight-loss-medication